A Study of HH-120 Nasal Spray in Close Contacts of Those Diagnosed With COVID-19

Summary

This study is to evaluate the efficacy of post-exposure prevention and safety of HH-120 nasal spray in participants who are caregivers of hospitalized patients infected with SARS-CoV-2. HH-120 nasal spray are administrated 8-10 times to the participants per day until the discharge of the SARS-CoV-2 infected patients or confirmed infection of the participant, whichever occurs first.

Timeline

Start

2022-06-14

Primary completion

2023-02-06

Completion

2023-02-06

Drugs

Indications